Tubulis GmbH

Who : Gilead Sciences and Tubulis What : Gilead and Tubulis have entered into a licensing deal to develop an antibody-drug conjugate (ADC) with an undisclosed solid tumor target and a topoisomerase-1

Rising Leaders Home As a schoolboy, Dominik Schumacher loved science. As CEO of Tubulis GmbH , from very early on he was always on the lookout for commercial opportunities. One of In Vivo ’s 2024 R

Included for 2024 are investors, CEOs of small and mid-sized companies, rising employees in larger businesses, as well as individuals driving unique health initiatives worldwide. The 30 people below h

Recent biopharmaceutical venture capital financings reflect a worldly investment view, even at the $100m-plus mega-round level where the largest investments tend to be more frequent in the US. The six